Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2005-07-20
2010-02-02
Aeder, Sean E (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Reexamination Certificate
active
07655755
ABSTRACT:
The Breast Cancer Resistance Protein is described, as well as the cDNA encoding said protein. This protein has been found to confer resistance to cancer chemotherapeutic drugs.
REFERENCES:
patent: 5585479 (1996-12-01), Hoke
patent: 6060248 (2000-05-01), Lane
patent: 2003/0232362 (2003-12-01), Komatani et al.
patent: 94/10303 (1994-05-01), None
patent: 98/55614 (1998-12-01), None
patent: 99/58675 (1999-11-01), None
patent: 00/18912 (2000-04-01), None
patent: 00/36101 (2000-06-01), None
Doyle et al (PNAS, 1999, 96:2569).
Lazar et al (Molecular and Cellular Biology, 1988, 8:1247-1252).
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
Zips et al (In vivo, 2005, 19:1-7).
Brennan et al (Journal of Autoimmunity, 1989, vol. 2 suppl., pp. 177-186).
Zimmer (Cell Motility and the Cytoskeleton, 1991, vol. 20, pp. 325-337).
Eriksson et al (Diabetologia, 1992, vol. 35, pp. 143-147).
Hell et al (Laboratory Investigation, 1995, vol. 73, pp. 492-496).
Powell et al (Pharmacogenesis, 1998, vol. 8, pp. 411-421).
Carrere et al (Gut, 1999, vol. 44, pp. 545-551).
Vallejo et al (Biochimie, 2000, vol. 82, pp. 1129-1133).
Guo et al (Journal of Pharmacology and Experimental Therapeutics, 2002, vol. 300, pp. 206-212).
Jang et al (Clinical and Experimental Metastasis, 1997, vol. 15, pp. 469-483).
Greenbaum et al. (Genome Biology, 2003, vol. 4, Issue 9, pp. 117.1-117.8).
(Jansen, et al, 1995, Pediatric Res., 37(6):681-686).
Alberts et al. (Molecular Biology of the Cell, 3rd edition, 1994, p. 465).
Shantz and Pegg (Int J of Biochem and Cell Biol., 1999, vol. 31, pp. 107-122).
McClean and Hill (Eur J of Cancer, 1993, vol. 29A, pp. 2243-2247).
Fu et al (EMBO Journal, 1996, vol. 15, pp. 4392-4401).
O'Hare et al (J Mol Bio, Dec. 1984, 3:abstract).
Turid Knutsen et al., “Amplification of 4q21-q22 and the MXR Gene in Independently Derived Mitoxantrone-Resistant Cell Lines,”Genes, Chromosomes and Cancer, vol. 27, pp. 110-116.
Douglas D. Ross et al., “Atypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitaxantrone-Selected Cell Lines,”JNCI, Jan. 28, 1999, pp. 1-11, vol. 91, No. 5.
Rando Allikmets et al., “Characterization of the Human ABC Superfamily: Isolation and Mapping of 21 New Genes Using the Expressed Sequence Tags Database,”Human Molecular Genetics, 1996, pp. 1649-1655, vol. 5, No. 1.
S.P.C. Cole et al., “Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line,” Dec. 4, 1992, pp. 1650-1654, vol. 258.
Masayuki Nakagawa et al., “Reduced Intracellular Drug Accumulation in the Absence of P-Glycoprotein (mdrl) Overexpression in Mitoxantrone-Resistant Human MCF-7 Breast Cancer Cells,”Cancer Research, Nov. 15, 1992, pp. 6175-6181, vol. 51.
Chih-Hsin J. Yang et al., “Cross-Resistance to Campotothecin Analogues in a Mitoxantrone-Resistant Human Breast Carcinoma Cell Line Is Not Due to DNA Topoisomerase I Alterations,”Cancer Research, Sep. 15, 1995, pp. 4004-4009, vol. 55.
Yi-Nan Chen et al., “Characterization of Adriamycin-Resistant Human Breast Cancer Cells Which Display Overexpression of a Novel Resistance-Related Membrane Protein,”The Journal of Biological Chemistry, Jun. 15, 1999, pp. 10073-10080, vol. 265, No. 17.
Manfred Dietel et al., “Membrane Vesicle Formation Due Acluired Mitoxantrone Resistance in Human Gastric Carcinoma Cell Line EPG85-257,”Cancer Research, Sep. 15, 1990, pp. 6100-6106, vol. 50.
C. W. Taylor et al., “Different Mechanisms of Decreased Drug Accumulation in Doxorubicin and Mitoxantrone Resistant Variants of the MCF7 Human Breast Cancer Cell Line,” 1991, pp. 923-929, vol. 63.
Sridhar K. Radindran et al., “Fumitremorigin C Reverse Multidrug Resistance in Cells Transfected with the Breast Cancer Resistance Protein,”Cancer Research, Jan. 1, 2000, pp. 47-50, vol. 60.
Bernard W. Futscher et al., “Analysis of MRP mRNA in Mitoxantrone-Selected, Multidrug-Resistant Human Tumor Cells,”Biochemical Pharmacology, 1994, pp. 1601-1606, vol. 47.
William S. Dalton et al., “Cytogenetic and Penotypic Analysis of a Human Colon Carcinoma Cell Line Resistant to Mitoxantrone,”Cancer Research, Apr. 1, 1988, pp. 1882-1888, vol. 48.
Jong Seok Lee et al., “Reduced Drug Accumulation and Multidrug Resistance in Human Breast Cancer Cells without Associated P-Glycoprotein or MPR Overexpression,”Journal of Cellular Biochemistry, 1997, pp. 513-526, vol. 65.
Udo Kellner et al., “Decreased Drug Accumulation in a Mitoxantrone-Resistant Gastric Carcinoma Cell Line in the Absence of P-Glycoprotein,”Int. J. Cancer, 1997, pp. 817-824, vol. 71.
J. Ma et al., “Reduced Cellular Accumulation of Topotecan: A Novel Mechanism of Resistance in a Human Ovarian Cancer Cell Line,”British Journal of Cancer, 1998, pp. 1645-1652, vol. 77(10).
Sridhar K. Rabindran et al., “Reversal of a Novel Multidrug Resistance Mechanism in Human Colon Carcinoma Cells by Fumitremorgin C,”Cancer Research, Dec. 15, 1998, pp. 5850-5858, vol. 58.
Marc Maliepaards et al., “Overexpression of the BCRP/MXR/ABCP Gene in a Toptecan-Selected Ovarian Tumor Cell Line,”Cancer Research, Sep. 15, 1999, pp. 4559-4563, vol. 59.
H Lage et al., “Expression of the Novel Mitoxantrone Resistance Associated Gene MXR7 in Colorectal Malignancies,”Intnl. Journal of Clinical Pharmacology and Therapeutics, 1998, pp. 58-60, vol. 36, No. 1.
John D. Allen et al., “The Mouse bcrp1/Mxr/Abcp Gene: Amplification and Overexpession in Cell Lines Selected Resistance Toptecan, Mitoxantrone or Doxorubicin,”Cancer Research, Sep. 1, 1999, pp. 4237-4424.
Lori A. Hazlehurst et al., “Multiple Mechanisms Confer Drug Resistance to Mitoxantrone in the Human 8226 Myeloma Cell Line,”Cancer Research, Mar. 1, 2000, pp. 1-8, vol. 59.
Erasmus Schneider et al., “Multidrug Resistance-Associated Protein Gene Overexpression and Reduced Drug Sensitivity of Topoisomerase II in a Human Breast Carcinoma MCF7 Cell Line Selected for Etoposide Resistance,”Cancer Research, Jan. 1, 1994, pp. 152-158, vol. 54.
Craig R. Fairchild et al., “Isolated of Amplified and Overexpressed DNA Sequences from Adriamycin-Resistant Human Breast Cancer Cells,”Cancer Research, Oct. 1, 1987, pp. 5141-5148, vol. 47.
P.S. Holm et al., Reversion of Multidrug Resistance in the P-glycoprotein-positive Human Pancreatic Cell Line 1 (EPP85-181RDB) by Introduction of a Hammerhead Ribzyme.
D.D. Ross, “Novel Mechanisms of Drug Resistance in Leukemia,” 2000.
“Cloning of DNA Sequences from the White Locus ofD. melanogasterby a Novel and General Method,”Cell, Sep. 1981, pp. 693-704, vol. 25.
E.L. Pugh et al., “Studies of the Mechanism of Fatty Acid Synthesis,”The Journal of Biological Chemistry, Dec. 1965, vol. 240, No. 12.
Devin O'Hare, “DNA Sequence of the White Locus ofDrosophila melanogaster,”J. Mol. Biol., pp. 437-455, vol. 180.
“Camptothecin Resistance: Role of the ATP-binding Cassette (ABC), Mitoxantrone-Resistance Half Transporter (MXR), and Potential for Glucuronidation in MXR-expressing Cells,”Cancer Research, Dec. 1, 1999, pp. 5938-5946, vol. 59.
June L. Biedler et al., “Cellular Resistance to Actinomycin D in Chinese Hamster Cells in Vitro: Cross Resistance, Radioautographic and Cytogenetic Studies,”Cancer Research, Apr. 1970, pp. 1174-1184, vol. 30.
Craig R. Fairchild et al., “Isolation of Amplified and Overexpressed DNA Sequences from Adriamycin-Resistant Human Breast Cancer Cells,”Cancer Research, Oct. 1, 1987, pp. 5141-5148, vol. 47.
W. Grzydon Harker et al., “Multidrug Resistance in Mitoxantrone-Selected HL-60 Leukemia Cells in the Absence of P-Glycoprotein Overexpression,”Cancer Research, Aug. 15, 1989, pp. 4542-4549, vol. 49.
Philip Skehan et al., “New
Abruzzo Lynne V.
Doyle L. Austin
Ross Douglas D.
Aeder Sean E
University of Maryland Baltimore
LandOfFree
Breast cancer resistance protein (BCRP) and the DNA which... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Breast cancer resistance protein (BCRP) and the DNA which..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Breast cancer resistance protein (BCRP) and the DNA which... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4154689